menu search

LIAN / Why LianBio Stock Is Shooting Through the Roof This Week

Why LianBio Stock Is Shooting Through the Roof This Week
LianBio has entered into a major deal with Bristol Myers Squibb. Bristol Myers will pay $350 million for the rights to develop and commercialize LianBio's mavacamten treatment in select Asian countries and territories. Read More
Posted: Oct 27 2023, 08:32
Author Name: The Motley Fool
Views: 112276

LIAN News  

Why LianBio Stock Is Shooting Through the Roof This Week

By The Motley Fool
October 27, 2023

Why LianBio Stock Is Shooting Through the Roof This Week

LianBio has entered into a major deal with Bristol Myers Squibb. Bristol Myers will pay $350 million for the rights to develop and commercialize LianB more_horizontal

Why Is LianBio (LIAN) Stock Up 130% Today?

By InvestorPlace
October 24, 2023

Why Is LianBio (LIAN) Stock Up 130% Today?

Shares of LianBio (NASDAQ: LIAN ) — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inf more_horizontal

Why LianBio Stock Is Skyrocketing Today

By The Motley Fool
October 24, 2023

Why LianBio Stock Is Skyrocketing Today

LianBio entered into a deal to give Bristol Myers Squibb exclusive rights for mavacemten in China and other Asian markets. The small drugmaker will re more_horizontal

LianBio to Participate in Upcoming Investor Conferences

By GlobeNewsWire
June 1, 2023

LianBio to Participate in Upcoming Investor Conferences

SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovativ more_horizontal

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

By Zacks Investment Research
December 20, 2022

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is elig more_horizontal

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

By Seeking Alpha
March 2, 2022

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

By Seeking Alpha
March 2, 2022

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

By Seeking Alpha
March 2, 2022

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal


Search within

Pages Search Results: